sightULCERATIVE COLITIS•3d
27
votes
1.3k
seen
Obefazimod kept clinical remission 39–40 points above placebo at week 52
Obefazimod kept its advantage through a full year of phase 3 maintenance testing, moving the question beyond whether the oral drug works to where it fits in ulcerative colitis treatment. The result came from about 580 patients with moderate-to-severe disease who responded to eight weeks of once-daily treatment before being re-randomized for 44 more weeks.
At week 52, clinical remission was 39 percentage points above placebo at 25 mg and 40 points above placebo at 50 mg. The gaps across other measures ranged from 31 to 53 points, with every result at p<0.0001, including patients with and without prior advanced-therapy failure.
At week 52, clinical remission was 39 percentage points above placebo at 25 mg and 40 points above placebo at 50 mg. The gaps across other measures ranged from 31 to 53 points, with every result at p<0.0001, including patients with and without prior advanced-therapy failure.
Timeline2
4d
Week-44 remission data showed obefazimod retained activity across prior-treatment failures, including patients with four or more advanced-therapy failures.
3d
Phase 3 maintenance results reported week-52 clinical remission advantages of 39 and 40 percentage points over placebo for 25 mg and 50 mg, respectively.
1 comment
3d